ValiRx plc (AIM:VAL)

Market Cap	1.85M -29.5%
Revenue (ttm)	31.37K -37.0%
Net Income	-2.23M
EPS	-0.01
Shares Out	1.32B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,327,921
Open	0.1450
Previous Close	0.1400
Day's Range	0.1300 - 0.1500
52-Week Range	0.1300 - 0.8000
Beta	-0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 3, 2026

About ValiRx

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 11
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2025, ValiRx's revenue was 31,372, a decrease of -36.97% compared to the previous year's 49,775. Losses were -2.23 million, 16.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error